

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) An antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 of any one of (1) - (12):

(1) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 123, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 124, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 125;

(2) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 109, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 110, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 111;

(3) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 106, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 107, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 108;

(4) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 132, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 133, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 134;

(5) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 106, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 135, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 136;

(6) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 126, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 127, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 128;

(7) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 129, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 130, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 131;

(8) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 103, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 104, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 105;

(9) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 118, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 121, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 122;

(10) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 115, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 116, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 117;

(11) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 112, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 113, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 114; or

(12) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 118, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 119, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 120.

2. (Original) An antibody comprising a light chain variable region having CDRs 1, 2 and 3 of any one of (1) - (13):

(1) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 143, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(2) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 143, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 145;

(3) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 140, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 141, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 142;

(4) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 167, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 168, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 169;

(5) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 170, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 171;

(6) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 159, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 160, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 161;

(7) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 162, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 147, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 163;

(8) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 164, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 165, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 166;

(9) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 137, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 138, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 139;

(10) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 155, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 156, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 157;

(11) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 149, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 150, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151;

(12) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 146, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 147, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 148; or

(13) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 152, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 153, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 154.

3. (Original) An antibody selected from the group consisting of any one of (1) - (13):

(1) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 143, 144 and 158, respectively;

(2) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 109, 110 and 111, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 143, 144 and 145, respectively;

(3) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 106, 107 and 108, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 140, 141 and 142, respectively;

(4) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 132, 133 and 134, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 167, 168 and 169, respectively;

(5) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 106, 135 and 136, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 170, 144 and 171, respectively;

(6) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 126, 127 and 128, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 159, 160 and 161, respectively;

(7) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 129, 130 and 131, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 162, 147 and 163, respectively;

(8) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 129, 130 and 131, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 164, 165 and 166, respectively;

(9) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 103, 104 and 105, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 137, 138 and 139, respectively;

(10) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 118, 121 and 122, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 155, 156 and 157, respectively;

(11) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 115, 116 and 117, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 149, 150 and 151, respectively;

(12) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 112, 113 and 114, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 146, 147 and 148, respectively; and

(13) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 118, 119 and 120, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 152, 153 and 154, respectively.

4. (Original) An antibody having a heavy chain variable region of any one of (1) - (7):

(1) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 84;

(2) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 85;

(3) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 86;

(4) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 87;

(5) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 88;

(6) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 89; or

(7) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 90.

5. (Original) An antibody having a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92.

6. (Original) An antibody selected from the group consisting of the antibody of any one of (1) - (7):

(1) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 84 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(2) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 85 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(3) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 86 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(4) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(5) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 88 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(6) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 89 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92; and

(7) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 90 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92.

7. (Previously presented) The antibody as claimed in any one of Claims 1-6, which is a humanized antibody.

8. (Previously presented) An antibody having an activity equivalent to the activity of the antibody of claim 7, wherein one or more amino acid residues are substituted, deleted or added and/or inserted from the amino acid sequences set forth in claim 7.

9. (Original) A humanized antibody capable of binding to glypican 3.
10. (Original) An antibody capable of binding to a peptide consisting of the sequence of the amino acid residues 524 - 563 of glypican 3.
11. (Original) An antibody capable of binding to a peptide consisting of the sequence of the amino acid residues 537 - 563 of glypican 3.
12. (Previously presented) The antibody as claimed in Claim 10 which does not bind to a peptide consisting of the sequence of the amino acid residues 550 - 563 of glypican 3.
13. (Original) An antibody capable of binding to a peptide consisting of the sequence of the amino acid residues 544 - 553 of glypican 3.
14. (Original) An antibody capable of binding to a peptide consisting of the sequence of the amino acid residues 546 - 551 of glypican 3.
15. (Previously presented) The antibody as claimed in any one of Claims 9-14 and 33 which is a humanized antibody.
16. (Original) An antibody capable of binding to an epitope to which a second antibody is capable of binding, wherein said second antibody comprises a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 143, 144 and 158, respectively.



17. (Original) An antibody capable of binding to glypican 3 which has a high CDC activity against a cell expressing glypican 3.

18. (Original) An antibody capable of binding to glypican 3 which has a high ADCC activity against a cell expressing glypican 3.

19. (Currently amended) A polynucleotide coding for a heavy chain variable region or a light chain variable region of the antibody as claimed in claim 7 ~~or~~ 8.

20. (Previously presented) The polynucleotide as claimed in Claim 19 having the sequence set forth in any one of SEQ ID NOs: 11-21, 33-43, 55-59, 65-70 and 77-83.

21. (Currently amended) A cell-growth inhibitor comprising as an active ingredient the antibody as claimed in claim 7 ~~or~~ 8.

22. (Currently amended) An anticancer agent comprising as an active ingredient the antibody as claimed in claim 7 ~~or~~ 8.

23. (Original) The anticancer agent as claimed in Claim 22 for treatment of hepatoma.

24. (Original) A peptide comprising the amino acid sequence of the amino acid residues 524 - 563 of glypican 3.

25. (Original) A peptide comprising the amino acid sequence of the amino acid residues 537 - 563 of glypican 3.

26. (Original) A peptide comprising the amino acid sequence of the amino acid residues 544 - 553 of glypican 3.

27. (Original) A peptide comprising the amino acid sequence of the amino acid residues 546 - 551 of glypican 3.

28. (Original) An antibody comprising a light chain variable region having CDRs 1, 2 and 3 of any one of (1) - (15):

(1) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 174, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(2) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 175, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(3) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 176, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(4) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 177, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(5) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 178, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(6) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 179, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(7) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 180, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(8) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 181, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(9) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 182, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(10) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 183, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(11) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 184, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(12) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 185, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(13) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 186, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(14) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 187, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158;

(15) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 188, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 158.

29. (Original) An antibody selected from the group consisting of the antibody of (1) - (15):

(1) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 174, 144 and 158, respectively;

(2) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 175, 144 and 158, respectively;

(3) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 176, 144 and 158, respectively;

(4) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 177, 144 and 158, respectively;

(5) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 178, 144 and 158, respectively;

(6) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 179, 144 and 158, respectively;

(7) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 180, 144 and 158, respectively;

(8) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 181, 144 and 158, respectively;

(9) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 182, 144 and 158, respectively;

(10) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 183, 144 and 158, respectively;

(11) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 184, 144 and 158, respectively;

(12) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124, and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 185, 144, and 158, respectively;

(13) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124, and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 186, 144 and 158, respectively;

(14) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 187, 144 and 158, respectively; and

(15) an antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 188, 144 and 158, respectively.

30. (Original) An antibody having a light chain variable region selected from (1) - (15):

(1) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 191;

(2) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 192;

(3) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 193;

(4) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 194;

(5) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 195;

(6) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 196;

(7) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 197;

(8) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 198;

(9) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 199;

(10) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 200;

(11) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 201;

(12) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 202;

(13) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 203;

(14) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 204; and

(15) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 205.

31. (Original) An antibody having a light chain variable region selected from the group consisting of (1) - (15):

(1) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 191;

(2) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 192;

(3) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 193;

(4) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 194;

(5) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 195;

(6) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 196;

(7) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 197;

(8) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 198;

(9) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 199;

(10) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 200;

(11) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 201;

(12) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 202;

(13) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 203;

(14) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 204; and

(15) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 205;

and a heavy chain variable region selected from the group consisting of (1) - (7):

(1) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 84;

(2) a heavy chain variable region comprising; the amino acid sequence set forth in SEQ ID NO: 85;

(3) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 86;

(4) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 87;

(5) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 88;

(6) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 89; and



(7) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 90.

32. (Original) The antibody as claimed in any one of Claims 28 - 31 which is a human antibody.

33. (Previously presented) The antibody as claimed in Claim 11 which does not bind to a peptide consisting of the sequence of the amino acid residues 550 - 563 of glypican 3.